Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics and Oxford BioTherapeutics (OBT) have entered into an agreement to discover novel antibody-drug conjugates (ADCs) targeting cancer.
Subscribe to our email newsletter
The agreement allows OBT to develop a range of monoclonal antibodies targeting novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP) database.
The antibodies generated by OBT will then be screened for activity using Seattle Genetics’ ADC technology.
As per the deal, both the companies will have same number of alternating options for choosing programs from among the preclinical ADCs identified for exclusive, worldwide development and commercialization.
Under the contract, each company is eligible to obtain undisclosed progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by the other party.
OBT CEO Christian Rohlff said they are looking forward to working with Seattle Genetics to provide improved therapies for patients suffering from cancer.